Effect of the Melanocortin 4-Receptor Ile269Asn Mutation on Weight Loss Response to Dietary, Phentermine and Bariatric Surgery Interventions
Authors:
- Itzel G. Salazar-ValenciaItzel G. Salazar-Valencia
- Hugo Villamil-RamírezHVHugo Villamil-Ramírez
- Francisco Barajas-OlmosFBFrancisco Barajas-Olmos
- Martha Guevara-CruzMGMartha Guevara-Cruz
- Luis R. Macias-KaufferLMLuis R. Macias-Kauffer
- Humberto García-OrtizHGHumberto García-Ortiz
- Omar Hernández-VergaraOHOmar Hernández-Vergara
- David Alberto Díaz de Sandy-GalánDSDavid Alberto Díaz de Sandy-Galán
- Paola León-MimilaPLPaola León-Mimila
- Federico Centeno-CruzFCFederico Centeno-Cruz
- Luis E. González-SalazarLGLuis E. González-Salazar
- Rocío Guizar-HerediaRGRocío Guizar-Heredia
Open Access
Abstract
The loss of function melanocortin 4-receptor (MC4R) Ile269Asn mutation has been proposed as one of the most important genetic contributors to obesity in the Mexican population. However, whether patients bearing this mutation respond differently to weight loss treatments is unknown. We tested the association of this mutation with obesity in 1683 Mexican adults, and compared the response of mutation carriers and non-carriers to three different weight loss interventions: dietary restriction intervention, phentermine 30 mg/day treatment, and Roux-en-Y gastric bypass (RYGB) surgery. The Ile269Asn mutation was associated with obesity [OR = 3.8, 95% CI (1.5–9.7), p = 0.005]. Regarding interventions, in the dietary restriction group only two patients were MC4R Ile269Asn mutation carriers. After 1 month of treatment, both mutation carriers lost weight: −4.0 kg (−2.9%) in patient 1, and −1.8 kg (−1.5%) in patient 2; similar to the mean weight loss observed in six non-carrier subjects (−2.9 kg; −2.8%). Phentermine treatment produced similar weight loss in six carriers (−12.7 kg; 15.5%) and 18 non-carriers (−11.3 kg; 13.6%) after 6 months of pharmacological treatment. RYGB also caused similar weight loss in seven carriers (29.9%) and 24 non-carriers (27.8%), 6 months after surgery. Our findings suggest that while the presence of a single MC4R loss of function Ile269Asn allele significantly increases obesity risk, the presence of at least one functional MC4R allele seems sufficient to allow short-term weight loss in response to dietary restriction, phentermine and RYGB. Thus, these three different interventions may be useful for the short-term treatment of obesity in MC4R Ile269Asn mutation carriers.Keywords
Funding Information
- CONACyT-PEI (230129, 289699, 777140)
- CONACYT-FOSISS (230129, 289699, 777140)
- CONACYT scholarship (230129, 289699, 777140)
This publication has 48 references indexed in Scilit:
- RFMix: A Discriminative Modeling Approach for Rapid and Robust Local-Ancestry InferenceThe American Journal of Human Genetics, 2013
- Melanocortin-4 Receptor Mutations and Polymorphisms Do Not Affect Weight Loss after Bariatric SurgeryPLOS ONE, 2012
- The ABCA1 Gene R230C Variant Is Associated with Decreased Risk of Premature Coronary Artery Disease: The Genetics of Atherosclerotic Disease (GEA) StudyPLOS ONE, 2012
- Melanocortin-4 Receptor Signaling Is Required for Weight Loss after Gastric Bypass SurgeryThe Journal of Clinical Endocrinology & Metabolism, 2012
- Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)Obesity, 2012
- Prevalence of Melanocortin-4 Receptor Deficiency in Europeans and Their Age-Dependent Penetrance in Multigenerational PedigreesDiabetes, 2008
- Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiencyJournal of Clinical Investigation, 2000
- Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesityJournal of Clinical Investigation, 2000
- Overeating and Obesity from Damage to a Noradrenergic System in the BrainScience, 1973
- Eating or Drinking Elicited by Direct Adrenergic or Cholinergic Stimulation of HypothalamusScience, 1960